An interventional study of Hand grip strength assessments using a dynamometer in Pancreatic Ductal Adenocarcinoma (PDAC) and Hand Grip Strength, sponsored by British Columbia Cancer Agency. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by British Columbia Cancer Agency · Not applicable, Interventional, and Basic science
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:
Participants will squeeze a device with their hand to measure their hand grip strength and complete questionnaires about their well-being when they are seen in clinic for their regular medical care for PDAC.
331 studies on the registry are indexed under Cachexia; 75 are open to participants now.
This study's planned enrollment of 50 is below the median of 74 across 226 interventional studies indexed under Cachexia.
Browse Cachexia studies →British Columbia Cancer Agency is the lead sponsor of 152 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study arm all participants are enrolled into. Participants will complete hand grip strength assessments and questionnaires.
Device: Hand grip strength assessments using a dynamometer
Squeeze a dynamometer with one hand to measure hand grip strength.
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 6 Months From Treatment Start Date
The percentage of participants with hand grip strength (HGS) test results at 6 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the 6-month follow-up assessment.
Frequency of Participants with Hand Grip Strength (HGS) Measurements at Study Baseline
The percentage of participants with hand grip strength (HGS) test results at study baseline. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: At the time of the baseline assessment for the study.
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 3 Months From Treatment Start Date
The percentage of participants with hand grip strength (HGS) test results at 3 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the 3-month follow-up assessment.
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 9 Months From Treatment Start Date
The percentage of participants with hand grip strength (HGS) test results at 9 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the 9-month follow-up assessment.
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 12 Months From Treatment Start Date
The percentage of participants with hand grip strength (HGS) test results at 12 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the 12-month follow-up assessment.
Proportion of Participants with Sarcopenia Using CT Image Alone (Sarcopenia CT)
The percentage of participants at each timepoint that meet the criteria for sarcopenia using the established definitions determined by CT image alone, namely the sex- and BMI-specific cut-off points developed by Caan et al. (2017).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Proportion of Participants with Sarcopenia Using Physical Function Alone (Sarcopenia P)
The percentage of participants at each timepoint that meet the criteria for sarcopenia using the definition of the Sarcopenia Definitions and Outcomes Consortium (SDOC) (Bhasin et al. 2020).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Proportion of Participants with Sarcopenia Using a Combination of CT Image and Physical Function (Sarcopenia COMB)
The percentage of participants at each timepoint that meet the criteria for sarcopenia using the definition by the European Working Group on Sarcopenia in Older Adults (EWGSOP2) (Cruz-Jentoft et al. 2019), which is supported by the Asian Working Group for Sarcopenia (Chen et al. 2019), and the Australian and New Zealand Society for Sarcopenia and Frailty Research (Zanker et al. 2023a, Zanker et al. 2023b).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Index (SMI)
The change in hand grip strength (HGS) for each unit of increase in skeletal muscle index (SMI). Hand grip strength is measured in kilograms with a hand-held dynamometer. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Density (SMD)
The change in hand grip strength (HGS) for each unit of increase in skeletal muscle density (SMD). Hand grip strength is measured in kilograms with a hand-held dynamometer. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Gauge (SMG)
The change in hand grip strength (HGS) for each unit of increase in skeletal muscle gauge (SMG). Hand grip strength is measured in kilograms with a hand-held dynamometer. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Visceral Adipose Tissue (VAT)
The change in hand grip strength (HGS) for each unit of increase in visceral adipose tissue (VAT). Hand grip strength is measured in kilograms with a hand-held dynamometer. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Subcutaneous Adipose Tissue (SAT)
The change in hand grip strength (HGS) for each unit of increase in subcutaneous adipose tissue (SAT). Hand grip strength is measured in kilograms with a hand-held dynamometer. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Intermuscular Adipose Tissue (IMAT)
The change in hand grip strength (HGS) for each unit of increase in intermuscular adipose tissue (IMAT). Hand grip strength is measured in kilograms with a hand-held dynamometer. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Progression-Free Survival (PFS)
The change in hand grip strength (HGS) for each unit of increase in progression-free survival (PFS). Hand grip strength is measured in kilograms with a hand-held dynamometer. Progression-free survival is the length of time from the first dose of treatment until the date of clinical progression.
Time frame: From the date anti-cancer therapy is initiated until the date of clinical progression, withdrawal, date of death, or end of study, whichever comes first, assessed up to 26 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Overall Survival (OS)
The change in hand grip strength (HGS) for each unit of increase in overall survival (OS). Hand grip strength is measured in kilograms with a hand-held dynamometer. Overall survival is the length of time from the initiation of treatment that participants survive.
Time frame: From the date anti-cancer therapy is initiated until the date of death or end of study, whichever comes first, assessed up to 26 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Objective Response Rate (ORR)
The change in hand grip strength (HGS) for each unit of increase in objective response rate (ORR). Hand grip strength is measured in kilograms with a hand-held dynamometer. Objective response rate is the proportion of participants who have a complete or partial response to treatment.
Time frame: From the date of the baseline assessment scan until the date of clinical progression, withdrawal, date of death, or end of study, whichever comes first, assessed up to 26 months.
Difference in Hand Grip Strength (HGS) Between Treatment Regimens
The difference in the amount of hand grip strength (HGS) between participants receiving different treatment regimens. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Tumour Stage
The change in hand grip strength (HGS) for each unit of increase in tumour stage as defined by the American Joint Committee on Cancer (AJCC). Hand grip strength is measured in kilograms with a hand-held dynamometer. Tumour stage describes the extent of cancer growth and spread.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Tumour Grade
The change in hand grip strength (HGS) for each unit of increase in tumour grade as defined by a four-tier grading system. Hand grip strength is measured in kilograms with a hand-held dynamometer. Tumour grade describes the appearance of cancer cells and their expected growth rate.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Difference in Hand Grip Strength (HGS) Between Sites of Metastasis
The difference in the amount of hand grip strength (HGS) between participants with different sites of metastasis. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Hand Grip Strength (HGS)
The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)
The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)
The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)
The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)
The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)
The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)
The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)
The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)
The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)
The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in hand grip strength (HGS). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Hand Grip Strength (HGS)
The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in hand grip strength (HGS). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Hand Grip Strength (HGS)
The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in hand grip strength (HGS). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Hand grip strength is measured in kilograms with a hand-held dynamometer.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)
The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)
The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)
The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)
The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)
The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)
The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)
The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)
The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)
The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)
The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle index (SMI). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Index (SMI)
The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle index (SMI). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Index (SMI)
The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle index (SMI). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Skeletal muscle index estimates overall muscle mass by dividing skeletal muscle area (SMA) or skeletal muscle mass (SMM) by height squared. SMI is measured in cm\^2/m\^2 and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)
The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)
The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)
The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)
The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)
The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)
The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)
The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)
The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)
The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)
The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle density (SMD). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Density (SMD)
The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle density (SMD). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Density (SMD)
The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle density (SMD). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Skeletal muscle density measures muscle composition, which includes the amount of fat and non-fat tissue within the muscle. SMD is measured in Hausefield Units (HU) and is calculated from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)
The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)
The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)
The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)
The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)
The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)
The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)
The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)
The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)
The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)
The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in skeletal muscle gauge (SMG). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Gauge (SMG)
The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle gauge (SMG). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Gauge (SMG)
The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in skeletal muscle gauge (SMG). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Skeletal muscle gauge is a measure of both skeletal muscle quantity and quality. SMG is calculated as the product of skeletal muscle index (SMI) and skeletal muscle density (SMD) and so is indirectly calculated from CT imaging of the third lumbar vertebra (L3). SMG is measured in Hausefield Units (HU)\*cm\^2/m\^2.
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)
The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)
The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)
The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)
The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)
The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)
The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)
The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)
The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)
The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)
The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in visceral adipose tissue (VAT). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Visceral Adipose Tissue (VAT)
The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in visceral adipose tissue (VAT). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Visceral Adipose Tissue (VAT)
The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in visceral adipose tissue (VAT). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Visceral adipose tissue is fat that is stored deep within the abdominal cavity and surrounds abdominal organs. VAT assesses the volume of fat in the body. VAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)
The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)
The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)
The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)
The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)
The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)
The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)
The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)
The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)
The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)
The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Subcutaneous Adipose Tissue (SAT)
The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Subcutaneous Adipose Tissue (SAT)
The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in subcutaneous adipose tissue (SAT). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Subcutaneous adipose tissue is the layer of fat located directly beneath the skin, between the dermis and muscles. SAT assesses fat distribution in the body. SAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in quality of life, as measured by the global health status from the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The global health status measure (QL2) ranges in score from 0 to 100 with higher scores indicating a higher quality of life. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in physical functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The physical functioning scale (PF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in role functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The role functioning scale (RF2) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Role functioning measures a person's ability to participate in daily life. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in emotional functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The emotional functioning scale (EF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in cognitive functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The cognitive functioning scale (CF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in social functioning, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The social functioning scale (SF) ranges from 0 to 100 with higher scores indicating a higher/healthy level of functioning. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in fatigue, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for fatigue (FA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in nausea and vomiting, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for nausea and vomiting (NV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in pain, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for pain (PA) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in dyspnoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of dyspnoea (DY) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in insomnia, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of insomnia (SL) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in appetite loss, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of appetite loss (AP) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in constipation, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of constipation (CO) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in diarrhoea, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of diarrhoea (DI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)
The change in financial difficulties, as measured by the EORTC QLQ-C30 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom item of financial difficulties (FI) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)
The change in food aversion, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for food aversion (AV) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)
The change in eating and weight loss worry, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for eating and weight loss worry (EW) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)
The change in eating difficulties, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for eating difficulties (EAT) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)
The change in loss of control, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for loss of control (LC) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)
The change in physical decline, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The symptom scale for physical decline (PHY) ranges from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)
The change in dry mouth, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The single item measure of dry mouth (DM) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)
The change in indigestion/heartburn, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The single item measure of indigestion/heartburn (IND) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)
The change in forcing self to eat, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The single item measure of forcing self to eat (FOR) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)
The change in a participant's perception of receiving inadequate information about their weight loss from their care team, as measured by the EORTC QLQ-CAX24 questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). The single item measure of receiving inadequate information about weight loss (INF) ranges in score from 0 to 100 with higher scores indicating a high level of symptomatology or problems. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Intermuscular Adipose Tissue (IMAT)
The change in quality of life, as measured by the Index Value from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). In Canada, the Index Value ranges from -0.148 to 0.949 with larger and more positive numbers indicating better health. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Intermuscular Adipose Tissue (IMAT)
The change in quality of life, as measured by the visual analogue scale (EQ-VAS) from the EuroQol EQ-5D-5L questionnaire, for each unit of increase in intermuscular adipose tissue (IMAT). EQ-VAS ranges from 0 to 100 with larger scores indicating better health. Intermuscular adipose tissue is fat that is located between muscle groups and underneath the deep fascia surrounding them. IMAT assesses the accumulation of fat in the body. IMAT is measured in cm\^2 from CT imaging of the third lumbar vertebra (L3).
Time frame: From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.
Plan to share: No — Only aggregate data will be shared with other researchers.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.
Of 75 non-industry interventional studies with no phase under Cachexia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 49. This study's planned 16 months is below that.
Counting every sponsor, half of 77 studies reached it within 19 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
British Columbia Cancer Agency →